<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308229</url>
  </required_header>
  <id_info>
    <org_study_id>MIN0803</org_study_id>
    <nct_id>NCT01308229</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of the Nile PAX Drug-Eluting Coronary Bifurcation Stent</brief_title>
  <acronym>BIPAX</acronym>
  <official_title>Assessment of the Safety and Efficacy of the Nile PAX® Drug Eluting Coronary Bifurcation Stent System for the Treatment of Single de Novo Bifurcation Lesions in Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MINVASYS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MINVASYS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the safety and efficacy of the Nile PAX® Drug Eluting
      Coronary Bifurcation Stent System for the treatment of single de novo bifurcation lesions in
      native coronary arteries with a main branch reference vessel diameter of 2.5-3.5 mm and side
      branch reference vessel diameter of 2.0-3.0 mm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BIPAX clinical trial is a prospective, non-randomized, multicenter, clinical trial
      evaluating the investigational coronary bifurcation device Nile PAX® in patients with main
      branch reference vessel diameters &gt;= 2.5 mm and &lt;= 3.5 mm, side branch reference vessel
      diameters &gt;= 2.0 and &lt;= 3.0 and lesion length &lt;= 14 mm. The trial allows the treatment of a
      single de novo bifurcation lesion in native coronary arteries following the provisional
      T-stenting technique with mandatory pre-dilatation of the main branch. In case the side
      branch requires a stent the treatment will be completed when possible with a Delta PAX® Drug
      Eluting Side Branch Stent.

      The BIPAX clinical trial will enroll 100 patients. All patients will receive Quantitative
      Coronary Angiography (QCA) after stent implantation and at 9 months follow-up. All patients
      will have a clinical follow-up at 1, 6, 9 and 12 months and subsequently every year up to 5
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic restenosis rate (%)</measure>
    <time_frame>9 months post-procedure</time_frame>
    <description>Angiographic restenosis rate of the main branch and side branch by Quantitative Coronary Angiography (QCA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Vessel Failure (TVF)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>9 months after procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute success (device, lesion, and procedure)</measure>
    <time_frame>at procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic in-stent Late Lumen Loss (LLL)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum luminal diameter (MLD)</measure>
    <time_frame>9 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic parameters</measure>
    <time_frame>9 months post-procedure</time_frame>
    <description>Angiographic parameters (in-stent and in-segment) including percent Diameter Stenosis (%DS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE) rate</measure>
    <time_frame>30 days and 9 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Nile PAX®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nile PAX® paclitaxel-eluting coronary stent</intervention_name>
    <description>Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions</description>
    <arm_group_label>Nile PAX®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo bifurcation lesions following the Medina classification except (0,0,1).

          -  Maximum one bifurcation lesion per patient.

          -  Single bifurcation lesion per vessel.

          -  The patient is at least 18 years of age. The patient has clinical evidence of ischemic
             heart disease, stable or unstable angina, silent ischemia, or a positive functional
             trial.

          -  The patient is an acceptable candidate for percutaneous transluminal coronary
             angioplasty (PTCA), stenting, and emergent coronary artery bypass graft (CABG)
             surgery.

          -  The patient or patient's legal representative has been informed of the nature of the
             trial and agrees to its provisions and has provided written informed consent as
             approved by the Institutional Review Board/Ethics Committee (IRB/EC) of the respective
             clinical site.

          -  The patient agrees to return to the same research facility for all required
             post-procedure follow-up visits.

        Exclusion Criteria:

          -  De novo bifurcation lesion Medina (0,0,1).

          -  Left main bifurcation.

          -  Heavily calcified lesions.

          -  Severe tortuous lesions.

          -  Documented left ventricular ejection fraction (LVEF) &lt; 30% at most recent evaluation.

          -  Women of childbearing potential.

          -  Chronic total occlusion (CTO).

          -  Previous PCI of the target lesion.

          -  Second lesion requiring treatment in target vessel.

          -  Second bifurcation lesion requiring treatment.

          -  Currently participating in an investigational drug or another device trial that has
             not completed the primary endpoint or that clinically interferes with the current
             trial endpoints; or requires coronary angiography, IVUS or other coronary artery
             imaging procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean FAJADET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dante Pazzanese de Cardiologia</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01412180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique d'Evecquemont</name>
      <address>
        <city>Evecquemont</city>
        <zip>78740</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Cardiologique du Nord</name>
      <address>
        <city>Saint Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casa di Cura Montevergine</name>
      <address>
        <city>Mercogliano</city>
        <zip>83013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thorax Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>300DR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karol Marcinkowski University of Medical Sciences</name>
      <address>
        <city>Poznań</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall D´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bifurcation</keyword>
  <keyword>Dedicated</keyword>
  <keyword>Drug-eluting stent</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Coronary artery stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

